The Value Of Triggering Receptor Expressed On Myeloid Cells 1 On Diagnosis And Prognosis Of Acute Myocardial Infarction

Objective: To screen out a new biomarker through bioinformatics and explore its value in the diagnosis and prognosis of acute myocardial infarction(AMI).Methods: GSE66360,GSE61144 and GSE60993 were downloaded from the GEO database and analyzed for differentially expressed genes(DEGs)by R software between AMI group and the normal group using R software.147 patients who were enrolled in the Cardiology Department of Zhongda Hospital between October 2018 and June 2019 according to the inclusion and exclusion criteria were divided into normal group(n=35),STEMI group(n=68)and NSTEMI group(n=44).Blood sample of each patient was collected,and all patients were followed up for 6 months.Results:(1)Bioinformatics analysis suggested that TREM1 was an important DEG between the normal population and patients with AMI.(2)TREM1 expression was significantly increased(P<0.001)in the STEMI and NSTEMI groups,compared with the normal group.(3)TREM1 expression was positively correlated with age,fasting plasma glucose(FPG),glycosylated hemoglobin(Hb AC),blood urea nitrogen(BUN),uric acid(UA),brain natriuretic peptide(BNP),and left atrial diameter(LA),and negatively correlated with Apo A1 and Albumin(ALB),and not correlated with Gensini score.(4)Multiple linear regression showed that UA and Hb AC levels were two independent factors affecting TREM1 expression(P=0.001).(5)ROC curves showed that TREM1 had a diagnostic significance for AMI(Area under curve [AUC]0.721,sensitivity 0.786,specificity 0.600,Youden index 0.386,P<0.001),especially in AMI patients without diabetes.(6)Cox regression showed that increased TREM1 expression was closely associated with one-month cardiogenic death(Hazard ratio[HR] 1.010,95% Confidence interval [CI] 1.004-1.016,P=0.001)and six-month major adverse cardiac events(MACE)(HR 1.006,95%CI 1.004-1.009,P<0.001).Conclusion: TREM1 is a potentially significant biomarker for diagnosis of AMI and may be closely associated with diabetes.TREM1 may also be helpful for predicting the one-month cardiac death and six-month MACE after AMI.